Home Print this page Email this page Users Online: 316
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2022  |  Volume : 10  |  Issue : 3  |  Page : 183-191

Tyrosine kinase targeting: A potential therapeutic strategy for diabetes

Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia

Correspondence Address:
Mohammad Althubiti
Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Prince Sultan Road 5096, Makkah
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/sjmms.sjmms_492_21

Rights and Permissions

Tyrosine kinase inhibitors (TKIs) have been studied extensively in cancer research, ultimately resulting in the approval of many drugs for cancer therapy. Recent evidence from reported clinical cases and experimental studies have suggested that some of these drugs have a potential role in diabetes treatment. These TKIs include imatinib, sunitinib, dasatinib, erlotinib, nilotinib, neratinib, and ibrutinib. As a result of promising findings, imatinib has been used in a phase II clinical trial. In this review, studies that used TKIs in the treatment of both types of diabetes are critically discussed. In addition, the different molecular mechanisms of action of these drugs in diabetes models are also highlighted to understand their antidiabetic mode of action.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded314    
    Comments [Add]    

Recommend this journal